Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies

References

• Mechoulam R. The pharmacohistory of Cannabis sativa. In: Cannabis as Therapeutic Agents. Mechoulam R (Ed.). CRC Press, FL, USA 1–19 (1986).
   Google Scholar
• Belenko S. Drugs and Drug Policy in America: a Documentory History. Belenko S (Ed.). Greenwood Press, CA, USA (2000).
   Google Scholar
• Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’. Prostaglandins Leukot. Essent. Fatty Acids53(1), 1–11 (1995).
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best. Pract. Res. Clin. Endocrinol. Metab.23(1), 1–15 (2009).
   PubMed Web of Science ®Google Scholar
• Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol. Res.60(2), 117–125 (2009).
   PubMed Web of Science ®Google Scholar
• Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut57(8), 1140–1155 (2008).
   PubMed Web of Science ®Google Scholar
• Storr MA, Yüce B, Andrews CN, Sharkey KA. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol. Motil.20(8), 857–868 (2008).
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature346(6284), 561–564 (1990).
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature365(6441), 61–65 (1993).
   PubMed Web of Science ®Google Scholar
• Casu MA, Porcella A, Ruiu S et al. Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. Eur. J. Pharmacol.459(1), 97–105 (2003).
   PubMed Web of Science ®Google Scholar
• Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J. Comp. Neurol.448(4), 410–422 (2002).
   PubMed Web of Science ®Google Scholar
• Wright K, Rooney N, Feeney M et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology129(2), 437–453 (2005).
   PubMed Web of Science ®Google Scholar
• Kulkarni-Narla A, Brown DR. Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons. Neurosci. Lett.308(3), 153–156 (2001).
   PubMed Web of Science ®Google Scholar
• Sibaev A, Yüce B, Kemmer M et al. Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon. Am. J. Physiol. Gastrointest. Liver Physiol.296(1), G119–G128 (2009).
   PubMed Web of Science ®Google Scholar
• Adami M, Frati P, Bertini S et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br. J. Pharmacol.135(7), 1598–1606 (2002).
   PubMed Web of Science ®Google Scholar
• MacNaughton WK, Van Sickle MD, Keenan CM, Cushing K, Mackie K, Sharkey KA. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am. J. Physiol. Gastrointest. Liver Physiol.286(5), G863–G871 (2004).
   Google Scholar
• Storr M, Sibaev A, Marsicano G et al. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am. J. Physiol. Gastrointest. Liver Physiol.286(1), G110–G117 (2004).
   Google Scholar
• Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut48(6), 859–867 (2001).
   PubMed Web of Science ®Google Scholar
• Baldassano S, Zizzo MG, Serio R, Mulè F. Interaction between cannabinoid CB1 receptors and endogenous ATP in the control of spontaneous mechanical activity in mouse ileum. Br. J. Pharmacol.158(1), 243–251 (2009).
   PubMedGoogle Scholar
• Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience90(3), 923–931 (1999).
   PubMed Web of Science ®Google Scholar
• Bridges D, Rice AS, Egertova M, Elphick MR, Winter J, Michael GJ. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience119(3), 803–812 (2003).
   PubMed Web of Science ®Google Scholar
• Binzen U, Greffrath W, Hennessy S, Bausen M, Saaler-Reinhardt S, Treede RD. Co-expression of the voltage-gated potassium channel Kv1.4 with transient receptor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat dorsal root ganglion neurons. Neuroscience142(2), 527–539 (2006).
   PubMedGoogle Scholar
• Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J. Neurosci.24(11), 2708–2715 (2004).
   PubMed Web of Science ®Google Scholar
• Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ. Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB1 and MCH receptor abundance. Am. J. Physiol. Gastrointest. Liver Physiol.290(6), G1289–G1297 (2006).
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Oland LD, Ho W et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology121(4), 767–774 (2001).
   PubMed Web of Science ®Google Scholar
• Pazos MR, Tolon RM, Benito C et al. Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa. J. Histochem. Cytochem.56(5), 511–516 (2008).
   PubMedGoogle Scholar
• Marquéz L, Suárez J, Iglesias M, Bermudez-Silva FJ, Rodríguez de FF, Andreu M. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One4(9), e6893 (2009).
   PubMed Web of Science ®Google Scholar
• Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am. J. Physiol. Gastrointest. Liver Physiol.291(2), G364–G371 (2006).
   PubMed Web of Science ®Google Scholar
• Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br. J. Pharmacol.153(2), 263–270 (2008).
   PubMed Web of Science ®Google Scholar
• Duncan M, Mouihate A, Mackie K et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am. J. Physiol. Gastrointest. Liver Physiol.295(1), G78–G87 (2008).
   Web of Science ®Google Scholar
• Duncan M, Davison JS, Sharkey KA. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment. Pharmacol. Ther.22(8), 667–683 (2005).
   PubMed Web of Science ®Google Scholar
• Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev.54(2), 161–202 (2002).
   PubMed Web of Science ®Google Scholar
• Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol.78(1), 43–50 (1997).
   PubMed Web of Science ®Google Scholar
• Boesmans W, Ameloot K, Van den Abbeel V, Tack J, Vanden Berghe P. Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. Neurogastroenterol. Motil.21(9), e958–e77 (2009).
   PubMed Web of Science ®Google Scholar
• Brown AJ. Novel cannabinoid receptors. Br. J. Pharmacol.152(5), 567–575 (2007).
   PubMed Web of Science ®Google Scholar
• Kreitzer FR, Stella N. The therapeutic potential of novel cannabinoid receptors. Pharmacol. Ther.122(2), 83–96 (2009).
   PubMedGoogle Scholar
• Godlewski G, Offertáler L, Wagner JA, Kunos G. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat.89(3–4), 105–111 (2009).
   PubMed Web of Science ®Google Scholar
• Chu ZL, Jones RM, He H et al. A role for β-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology148(6), 2601–2609 (2007).
   PubMed Web of Science ®Google Scholar
• Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes58(5), 1058–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjogren S et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol.152(7), 1092–1101 (2007).
   PubMed Web of Science ®Google Scholar
• Massa F, Marsicano G, Hermann H et al. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest.113(8), 1202–1209 (2004).
   PubMed Web of Science ®Google Scholar
• Izzo AA, Fezza F, Capasso R et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol.134(3), 563–570 (2001).
   PubMed Web of Science ®Google Scholar
• Mascolo N, Izzo AA, Ligresti A et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J.16(14), 1973–1975 (2002).
   PubMed Web of Science ®Google Scholar
• Izzo AA, Capasso F, Costagliola A et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology125(3), 765–774 (2003).
   PubMed Web of Science ®Google Scholar
• Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB(2)) protects against experimental colitis. Inflamm. Bowel. Dis.15(11), 1678–1685 (2009).
   PubMed Web of Science ®Google Scholar
• D’Argenio G, Petrosino S, Gianfrani C et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J. Mol. Med.85(5), 523–530 (2007).
   PubMed Web of Science ®Google Scholar
• Guagnini F, Valenti M, Mukenge S et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut55(7), 946–953 (2006).
   PubMed Web of Science ®Google Scholar
• Ligresti A, Bisogno T, Matias I et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology125(3), 677–687 (2003).
   PubMed Web of Science ®Google Scholar
• Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr. Opin. Pharmacol.1(6), 597–603 (2001).
   PubMedGoogle Scholar
• Zygmunt PM, Petersson J, Andersson DA et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature400(6743), 452–457 (1999).
   PubMed Web of Science ®Google Scholar
• Kimball ES, Wallace NH, Schneider CR, D’Andrea MR, Hornby PJ. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol. Motil.16(6), 811–818 (2004).
   PubMedGoogle Scholar
• D’Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J.20(3), 568–570 (2006).
   PubMed Web of Science ®Google Scholar
• McVey DC, Schmid PC, Schmid HH, Vigna SR. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J. Pharmacol. Exp. Ther.304(2), 713–722 (2003).
   PubMed Web of Science ®Google Scholar
• Izzo AA, Aviello G, Petrosino S et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J. Mol. Med.86(1), 89–98 (2008).
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Capasso R, Matias I et al. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br. J. Pharmacol.153(6), 1272–1280 (2008).
   PubMed Web of Science ®Google Scholar
• Izzo AA, Piscitelli F, Capasso R et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br. J. Pharmacol.158(2), 451–461 (2009).
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Bari M, Battista N, Finazzi-Agro A. Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood100(12), 4040–4048 (2002).
   PubMedGoogle Scholar
• Maccarrone M, De Petrocellis L, Bari M et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch. Biochem. Biophys.393(2), 321–328 (2001).
   PubMed Web of Science ®Google Scholar
• Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur. J. Clin. Pharmacol.64(1), 1–8 (2008).
   PubMedGoogle Scholar
• Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J.12(11), 1035–1044 (1998).
   PubMed Web of Science ®Google Scholar
• Di Marzo V, De Petrocellis L, Sepe N, Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J.316(3), 977–984 (1996).
   PubMedGoogle Scholar
• Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem.272(6), 3315–3323 (1997).
   PubMed Web of Science ®Google Scholar
• Nagy B, Fedonidis C, Photiou A et al. Capsaicin-sensitive primary sensory neurons in the mouse express N-acyl phosphatidylethanolamine phospholipase D. Neuroscience161(2), 572–577 (2009).
   PubMedGoogle Scholar
• Ahluwalia J, Urban L, Bevan S, Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur. J. Neurosci.17(12), 2611–2618 (2003).
   PubMedGoogle Scholar
• Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res.60(2), 77–84 (2009).
   PubMed Web of Science ®Google Scholar
• Aviello G, Matias I, Capasso R et al. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J. Mol. Med.86(4), 413–422 (2008).
   PubMedGoogle Scholar
• Fu J, Astarita G, Gaetani S et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J. Biol. Chem.282(2), 1518–1528 (2007).
   PubMed Web of Science ®Google Scholar
• Deutsch DG, Glaser ST, Howell JM et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem.276(10), 6967–6973 (2001).
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Lichtman AH. The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem. Phys. Lipids121(1–2), 135–148 (2002).
   PubMed Web of Science ®Google Scholar
• Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett.422(1), 69–73 (1998).
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem. J.331(1), 15–19 (1998).
   PubMed Web of Science ®Google Scholar
• Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids121(1–2), 149–158 (2002).
   PubMed Web of Science ®Google Scholar
• Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem.281(48), 36569–36578 (2006).
   PubMed Web of Science ®Google Scholar
• Duncan M, Thomas AD, Cluny NL et al. Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am. J. Physiol. Gastrointest. Liver Physiol.295(6), G1255–G1265 (2008).
   Google Scholar
• Glaser ST, Kaczocha M, Deutsch DG. Anandamide transport: a critical review. Life Sci.77(14), 1584–1604 (2005).
   PubMed Web of Science ®Google Scholar
• Kaczocha M, Glaser ST, Deutsch DG. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl Acad. Sci. USA106(15), 6375–6380 (2009).
   PubMed Web of Science ®Google Scholar
• Long JZ, Li W, Booker L et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol.5(1), 37–44 (2009).
   PubMed Web of Science ®Google Scholar
• Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol.2(1), 69–82 (2002).
   PubMed Web of Science ®Google Scholar
• Börner C, Höllt V, Sebald W, Kraus J. Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J. Leukoc. Biol.81(1), 336–343 (2007).
   PubMed Web of Science ®Google Scholar
• Wang S, Lim G, Mao J, Sung B, Yang L, Mao J. Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats. Pain131(1–2), 96–105 (2007).
   PubMedGoogle Scholar
• Hansen HH, Ikonomidou C, Bittigau P, Hansen SH, Hansen HS. Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J. Neurochem.76(1), 39–46 (2001).
   PubMedGoogle Scholar
• Darmani NA. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212–2. Eur. J. Pharmacol.430(1), 49–58 (2001).
   PubMed Web of Science ®Google Scholar
• Matias I, Cristino L, Di Marzo V. Endocannabinoids: some like it fat (and sweet too). J. Neuroendocrinol.20(Suppl. 1), 100–109 (2008).
   PubMed Web of Science ®Google Scholar
• Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am. J. Med.120(9 Suppl. 1), S18–S24 (2007).
   Web of Science ®Google Scholar
• Darmani NA, Johnson JC. Central and peripheral mechanisms contribute to the antiemetic actions of Δ9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur. J. Pharmacol.488(1–3), 201–212 (2004).
   PubMed Web of Science ®Google Scholar
• Sharkey KA, Cristino L, Oland LD et al. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur. J. Neurosci.25(9), 2773–2782 (2007).
   PubMed Web of Science ®Google Scholar
• Parker LA, Kwiatkowska M, Mechoulam R. Δ9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol. Behav.87(1), 66–71 (2006).
   PubMed Web of Science ®Google Scholar
• Storr M, Gaffal E, Saur D, Schusdziarra V, Allescher HD. Effect of cannabinoids on neural transmission in rat gastric fundus. Can. J. Physiol. Pharmacol.80(1), 67–76 (2002).
   PubMed Web of Science ®Google Scholar
• Fioramonti J, Bueno L. Role of cannabinoid receptors in the control of gastrointestinal motility and perception. Expert Rev. Gastroenterol. Hepatol.2(3), 385–397 (2008).
   PubMedGoogle Scholar
• Hinds NM, Ullrich K, Smid SD. Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br. J. Pharmacol.148(2), 191–199 (2006).
   PubMed Web of Science ®Google Scholar
• Croci T, Manara L, Aureggi G et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. J. Pharmacol.125(7), 1393–1395 (1998).
   PubMed Web of Science ®Google Scholar
• Manara L, Croci T, Guagnini F et al. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig. Liver Dis.34(4), 262–269 (2002).
   PubMedGoogle Scholar
• Capasso R, Matias I, Lutz B et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology129(3), 941–951 (2005).
   PubMed Web of Science ®Google Scholar
• Di Marzo V. Endocannabinoids: synthesis and degradation. Rev. Physiol Biochem. Pharmacol.160, 1–24 (2008).
   PubMed Web of Science ®Google Scholar
• Coruzzi G, Adami M, Guaita E et al. Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data. Dig. Dis. Sci.51(2), 310–317 (2006).
   PubMedGoogle Scholar
• Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology132(2), 615–627 (2007).
   PubMed Web of Science ®Google Scholar
• Darmani NA. Antiemetic action of D9-tetrahydrocannabinoid and synthetic cannabinoids in chemotherapy-induced nausea and vomiting. In: Biology of Marijuana: from Gene to Behavior. Onaivi ES (Ed.). Taylor and Francis, London, UK 356–389 (2002).
   Google Scholar
• Van Sickle MD, Duncan M, Kingsley PJ et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science310(5746), 329–332 (2005).
   PubMed Web of Science ®Google Scholar
• Fegley D, Gaetani S, Duranti A et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3´-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther.313(1), 352–358 (2005).
   PubMed Web of Science ®Google Scholar
• Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA. Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology (Berl.)190(2), 135–143 (2007).
   PubMed Web of Science ®Google Scholar
• Darmani NA, McClanahan BA, Trinh C, Petrosino S, Valenti M, Di Marzo V. Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology49(4), 502–513 (2005).
   PubMedGoogle Scholar
• Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol.6(2), 93–102 (2005).
   PubMed Web of Science ®Google Scholar
• Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin. Investig. Drugs17(1), 85–95 (2008).
   PubMed Web of Science ®Google Scholar
• Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur. J. Cancer Care (Engl.)17(5), 431–443 (2008).
   PubMed Web of Science ®Google Scholar
• Darmani NA. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by Δ(9)-tetrahydrocannabinol and other cannnabinoids. J. Pharmacol. Exp. Ther.300(1), 34–42 (2002).
   PubMedGoogle Scholar
• Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ323(7303), 16–21 (2001).
   PubMed Web of Science ®Google Scholar
• Chepyala P, Olden KW. Cyclic vomiting and compulsive bathing with chronic cannabis abuse. Clin. Gastroenterol. Hepatol.6(6), 710–712 (2008).
   PubMedGoogle Scholar
• Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut53(11), 1566–1570 (2004).
   PubMed Web of Science ®Google Scholar
• Sontineni SP, Chaudhary S, Sontineni V, Lanspa SJ. Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse. World J. Gastroenterol.15(10), 1264–1266 (2009).
   PubMed Web of Science ®Google Scholar
• Lehmann A, Blackshaw LA, Branden L et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology123(4), 1129–1134 (2002).
   PubMed Web of Science ®Google Scholar
• Partosoedarso ER, Abrahams TP, Scullion RT, Moerschbaecher JM, Hornby PJ. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J. Physiol.550(1), 149–158 (2003).
   PubMed Web of Science ®Google Scholar
• Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G. Effect of Δ9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br. J. Pharmacol.156(1), 153–162 (2009).
   PubMed Web of Science ®Google Scholar
• Rutkowska M, Fereniec-Golebiewska L. Involvement of nitric oxide in the gastroprotective effect of ACEA, a selective cannabinoid CB1 receptor agonist, on aspirin-induced gastric ulceration. Pharmazie64(9), 595–597 (2009).
   PubMedGoogle Scholar
• Rutkowska M, Fereniec-Goltbiewska L. ACEA (arachidonyl-2-chloroethylamide), the selective cannabinoid CB1 receptor agonist, protects against aspirin-induced gastric ulceration. Pharmazie61(4), 341–342 (2006).
   PubMedGoogle Scholar
• Dembinski A, Warzecha Z, Ceranowicz P et al. Cannabinoids in acute gastric damage and pancreatitis. J. Physiol. Pharmacol.57(Suppl. 5), 137–154 (2006).
   PubMedGoogle Scholar
• Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am. J. Gastroenterol.97(8), 1910–1915 (2002).
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology130(5), 1480–1491 (2006).
   PubMed Web of Science ®Google Scholar
• Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology130(5), 1377–1390 (2006).
   PubMed Web of Science ®Google Scholar
• Spiller R, Aziz Q, Creed F et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut56(12), 1770–1798 (2007).
   PubMed Web of Science ®Google Scholar
• Vassallo M, Camilleri M, Phillips S, Brown M, Chapman N, Thomforde G. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology102(1), 102–108 (1992).
   PubMed Web of Science ®Google Scholar
• Bazzocchi G, Ellis J, Villanueva-Meyer J, Reddy S, Mena I, Snape WJ. Effect of eating on colonic motility and transit in patients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations. Gastroenterology101(5), 1298–1306 (1991).
   PubMed Web of Science ®Google Scholar
• Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am. J. Gastroenterol.96(5), 1499–1506 (2001).
   PubMed Web of Science ®Google Scholar
• Bassotti G, Chistolini F, Marinozzi G, Morelli A. Abnormal colonic propagated activity in patients with slow transit constipation and constipation-predominant irritable bowel syndrome. Digestion68(4), 178–183 (2003).
   PubMed Web of Science ®Google Scholar
• Bazzocchi G, Ellis J, Villanueva-Meyer J et al. Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology98(3), 686–693 (1990).
   PubMed Web of Science ®Google Scholar
• Sullivan M, Cohen S, Snape WJ. Colonic myoelectrical activity in irritable-bowel syndrome. Effect of eating and anticholinergics. N. Engl. J. Med.298(16), 878–883 (1978).
   PubMed Web of Science ®Google Scholar
• Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br. J. Pharmacol.141(8), 1335–1345 (2004).
   PubMed Web of Science ®Google Scholar
• Grider JR, Mahavadi S, Li Y et al. Modulation of motor and sensory pathways of the peristaltic reflex by cannabinoids. Am. J. Physiol. Gastrointest. Liver Physiol297(3), G539–G549 (2009).
   PubMed Web of Science ®Google Scholar
• Wang A, Liao X, Xiong L et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC. Gastroenterol.8, 43 (2008).
   PubMed Web of Science ®Google Scholar
• Tyler K, Hillard CJ, Greenwood-Van Meerveld B. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur. J. Pharmacol.409(2), 207–211 (2000).
   PubMed Web of Science ®Google Scholar
• Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur. J. Pharmacol.384(1), 37–42 (1999).
   PubMed Web of Science ®Google Scholar
• Anand P, Aziz Q, Willert R, Van Oudenhove L. Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol. Motil.19(Suppl. 1), 29–46 (2007).
   PubMedGoogle Scholar
• Azpiroz F, Bouin M, Camilleri M et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol. Motil.19(Suppl. 1), 62–88 (2007).
   PubMedGoogle Scholar
• Aziz Q. Visceral hypersensitivity: fact or fiction. Gastroenterology131(2), 661–664 (2006).
   PubMedGoogle Scholar
• Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut51(Suppl. 1), i41–i44 (2002).
   PubMed Web of Science ®Google Scholar
• Holtmann G. IBS: a syndrome or many diseases? Best. Pract. Res. Clin. Gastroenterol.18(Suppl.), 91–97 (2004).
   PubMedGoogle Scholar
• Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ323(7303), 13–16 (2001).
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J. Pharmacol. Sci.106(2), 219–224 (2008).
   PubMed Web of Science ®Google Scholar
• Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol. Motil.18(10), 949–956 (2006).
   PubMed Web of Science ®Google Scholar
• Hillsley K, McCaul C, Aerssens J et al. Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol. Motil.19(9), 769–777 (2007).
   PubMed Web of Science ®Google Scholar
• Brusberg M, Arvidsson S, Kang D, Larsson H, Lindstrom E, Martinez V. CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents. J. Neurosci.29(5), 1554–1564 (2009).
   PubMed Web of Science ®Google Scholar
• Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am. J. Physiol. Gastrointest. Liver Physiol.293(1), G137–G145 (2007).
   PubMed Web of Science ®Google Scholar
• Camilleri M. Novel pharmacology: asimadoline, a κ-opioid agonist, and visceral sensation. Neurogastroenterol. Motil.20(9), 971–979 (2008).
   PubMed Web of Science ®Google Scholar
• Fichna J, Schicho R, Andrews CN et al. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating κ-opioid and cannabinoid receptors. Neurogastroenterol. Motil.21(12), 1326 (2009).
   PubMedGoogle Scholar
• Capasso R, Borrelli F, Cascio MG et al. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between κ-opioid and cannabinoid CB(1) receptors. Br. J. Pharmacol.155(5), 681–689 (2008).
   PubMedGoogle Scholar
• Miranda A, Nordstrom E, Mannem A, Smith C, Banerjee B, Sengupta JN. The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis. Neuroscience148(4), 1021–1032 (2007).
   PubMed Web of Science ®Google Scholar
• Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut57(7), 923–929 (2008).
   PubMed Web of Science ®Google Scholar
• Ravnefjord A, Brusberg M, Kang D et al. Involvement of the transient receptor potential vanilloid 1 (TRPV1) in the development of acute visceral hyperalgesia during colorectal distension in rats. Eur. J. Pharmacol.611(1–3), 85–91 (2009).
   PubMedGoogle Scholar
• Maione S, De Petrocellis L, de Novellis V et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol.150(6), 766–781 (2007).
   PubMed Web of Science ®Google Scholar
• Naidu PS, Booker L, Cravatt BF, Lichtman AH. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J. Pharmacol. Exp. Ther.329(1), 48–56 (2009).
   PubMed Web of Science ®Google Scholar
• Riordan SM, Kim R. Bacterial overgrowth as a cause of irritable bowel syndrome. Curr. Opin. Gastroenterol.22(6), 669–673 (2006).
   PubMedGoogle Scholar
• Verdu EF, Bercik P, Verma-Gandhu M et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut55(2), 182–190 (2006).
   PubMed Web of Science ®Google Scholar
• Ait-Belgnaoui A, Han W, Lamine F et al.Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut55(8), 1090–1094 (2006).
   PubMed Web of Science ®Google Scholar
• Kajander K, Korpela R. Clinical studies on alleviating the symptoms of irritable bowel syndrome. Asia Pac. J. Clin. Nutr.15(4), 576–580 (2006).
   PubMedGoogle Scholar
• Rousseaux C, Thuru X, Gelot A et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med.13(1), 35–37 (2007).
   PubMed Web of Science ®Google Scholar
• Camilleri M, Carlson P, McKinzie S et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am. J. Physiol. Gastrointest. Liver Physiol.294(1), G13–G19 (2008).
   PubMed Web of Science ®Google Scholar
• Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl Acad. Sci. USA99(12), 8394–8399 (2002).
   PubMed Web of Science ®Google Scholar
• Storr MA, Keenan CM, Emmerdinger D et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J. Mol. Med.86(8), 925–936 (2008).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology126(6), 1504–1517 (2004).
   PubMed Web of Science ®Google Scholar
• Croci T, Landi M, Galzin AM, Marini P. Role of cannabinoid CB1 receptors and tumor necrosis factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br. J. Pharmacol.140(1), 115–122 (2003).
   PubMed Web of Science ®Google Scholar
• Ihenetu K, Molleman A, Parsons ME, Whelan CJ. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur. J. Pharmacol.458(1–2), 207–215 (2003).
   PubMed Web of Science ®Google Scholar
• Mathison R, Ho W, Pittman QJ, Davison JS, Sharkey KA. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br. J. Pharmacol.142(8), 1247–1254 (2004).
   PubMed Web of Science ®Google Scholar
• Borrelli F, Aviello G, Romano B et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J. Mol. Med.87(11), 1111–1121 (2009).
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Izzo AA. Endocannabinoid overactivity and intestinal inflammation. Gut55(10), 1373–1376 (2006).
   PubMed Web of Science ®Google Scholar
• Ahmed FE. Colon cancer: prevalence, screening, gene expression and mutation, and risk factors and assessment. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev.21(2), 65–131 (2003).
   PubMed Web of Science ®Google Scholar
• Pisanti S, Malfitano AM, Grimaldi C et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best. Pract. Res. Clin. Endocrinol. Metab.23(1), 117–131 (2009).
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci.28(1), 39–45 (2007).
   PubMed Web of Science ®Google Scholar
• Greenhough A, Patsos HA, Williams AC, Paraskeva C. The cannabinoid Δ(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int. J. Cancer121(10), 2172–2180 (2007).
   PubMed Web of Science ®Google Scholar
• Joseph J, Niggemann B, Zaenker KS, Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol. Immunother.53(8), 723–728 (2004).
   PubMed Web of Science ®Google Scholar
• Patsos HA, Hicks DJ, Dobson RR et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut54(12), 1741–1750 (2005).
   PubMed Web of Science ®Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, Giiardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology107(4), 1183–1188 (1994).
   PubMed Web of Science ®Google Scholar
• Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res.60(18), 5040–5044 (2000).
   PubMed Web of Science ®Google Scholar
• Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res.68(15), 6468–6476 (2008).
   PubMed Web of Science ®Google Scholar
• Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, Haro A, Guzman M. Cannabinoids and ceramide: two lipids acting hand-by-hand. Life Sci.77(14), 1723–1731 (2005).
   PubMed Web of Science ®Google Scholar
• Cianchi F, Papucci L, Schiavone N et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor α-mediated ceramide de novo synthesis in colon cancer cells. Clin. Cancer Res.14(23), 7691–7700 (2008).
   PubMed Web of Science ®Google Scholar
• Notarnicola M, Messa C, Orlando A et al. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand. J. Gastroenterol.43(1), 66–72 (2008).
   PubMed Web of Science ®Google Scholar
• McPartland JM. Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship. PLOS One4(3), e5092 (2009).
   Google Scholar
• Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci.30(10), 515–527 (2009).
   PubMed Web of Science ®Google Scholar
• Capasso R, Borrelli F, Aviello G et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br. J. Pharmacol.154(5), 1001–1008 (2008).
   PubMedGoogle Scholar
• Riedel G, Fadda P, Killop-Smith S, Pertwee RG, Platt B, Robinson L. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br. J. Pharmacol.156(7), 1154–1166 (2009).
   PubMed Web of Science ®Google Scholar
• Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, Piomelli D. The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). Physiol. Behav.97(1), 121–124 (2009).
   PubMed Web of Science ®Google Scholar
• Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov.7(5), 438–455 (2008).
   PubMed Web of Science ®Google Scholar
• Li YY, Li YN, Ni JB et al. Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. Neurogastroenterol. Motil. DOI: 10.1111/j.1365–2982.2009.01419.x (2009) (Epub ahead of print).
   Google Scholar
• Yuece B, Sibaev A, Broedl UC et al. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterol. Motil.19(9), 744–753 (2007).
   PubMed Web of Science ®Google Scholar